Literature DB >> 34232758

Solitary Anosmia/Ageusia in Prison: Results From a COVID-19 Cluster.

Jamal K Gwathney1.   

Abstract

A prison setting with its congregate environment is at high risk for widespread transmission of respiratory illnesses. Identifying COVID-19 cases as early as possible and isolating cases and tracing contacts is critical to halting the spread of this disease. The Centers for Disease Control and Prevention (CDC) added new loss of taste or smell to its list of symptoms and, initially, only if associated with at least one of six other symptoms. The CDC has since updated the guidance to remove this qualifier as of May 13, 2020. New loss of taste or smell, alone, can help to identify COVID-19 cases. Solitary anosmia/ageusia should be strongly considered in routine symptom screening protocols for COVID-19.

Entities:  

Keywords:  COVID-19; SARS CoV-2; ageusia; anosmia; prison; smell; taste

Mesh:

Year:  2021        PMID: 34232758      PMCID: PMC9041382          DOI: 10.1089/jchc.20.05.0044

Source DB:  PubMed          Journal:  J Correct Health Care        ISSN: 1078-3458


  4 in total

1.  Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection.

Authors:  Giacomo Spinato; Cristoforo Fabbris; Jerry Polesel; Diego Cazzador; Daniele Borsetto; Claire Hopkins; Paolo Boscolo-Rizzo
Journal:  JAMA       Date:  2020-05-26       Impact factor: 56.272

2.  Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43.

Authors:  Mathieu Dubé; Alain Le Coupanec; Alan H M Wong; James M Rini; Marc Desforges; Pierre J Talbot
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

3.  Anosmia and ageusia are emerging as symptoms in patients with COVID-19: What does the current evidence say?

Authors:  Beth Russell; Charlotte Moss; Anne Rigg; Claire Hopkins; Sophie Papa; Mieke Van Hemelrijck
Journal:  Ecancermedicalscience       Date:  2020-04-03

4.  Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms.

Authors:  Carol H Yan; Farhoud Faraji; Divya P Prajapati; Christine E Boone; Adam S DeConde
Journal:  Int Forum Allergy Rhinol       Date:  2020-06-01       Impact factor: 5.426

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.